Ongoing Clinical Trials for Tachypnoea
This article provides information about ongoing clinical trials for patients experiencing tachypnoea and related emergency medical conditions. Currently, there is 1 active clinical trial investigating the use of phosphocreatine sodium in patients requiring emergency medical treatment for conditions such as rapid breathing, abnormal heart rates, and changes in consciousness. The trial is being conducted in Italy and aims to improve outcomes for patients facing critical health emergencies.
Clinical trial locations
Study on the Effect of Phosphocreatine Sodium and Sodium Chloride in Patients Treated by Medical Emergency Teams with Conditions like Rapid Breathing or Low Blood Pressure
This clinical trial is designed for patients experiencing serious medical emergencies that require immediate attention from medical emergency teams. The study is being conducted in Italy and focuses on evaluating whether phosphocreatine sodium can help improve recovery outcomes compared to a standard saline solution.
Main focus and goals: The primary aim of this trial is to determine whether treatment with phosphocreatine sodium can increase the number of days patients are alive and out of the hospital within 30 days after treatment. Phosphocreatine is a substance that may help improve energy supply to cells, which could be particularly beneficial during critical health situations. Researchers want to understand if this treatment can help patients recover more quickly and return to their normal lives sooner than those receiving standard care.
Who can participate (inclusion criteria):
- Patients must be at least 18 years old
- Must be admitted to the hospital but not in the intensive care unit at the time of enrollment
- Must provide written informed consent, either personally or through a legal representative
- Kidney function must be adequate, with serum creatinine levels of 2 mg/dl or less
- Must be experiencing at least one of the following emergency conditions: threatened airways, respiratory arrest, breathing rate less than 5 or more than 36 breaths per minute, heart rate less than 40 or more than 140 beats per minute, systolic blood pressure less than 90 mm Hg, sudden decrease in consciousness, or a drop of more than 2 points on the Glasgow Coma Scale
- Must have risk of or existing heart problems, including potential heart failure or cardiac arrest
Who cannot participate (exclusion criteria): The exclusion criteria mirror many of the inclusion criteria related to emergency conditions. Patients experiencing tachypnoea, tachycardia, very slow or very fast pulse rates, respiratory arrest, threatened airways, significantly low blood pressure, very slow breathing, or sudden falls in consciousness level are carefully evaluated to ensure they meet all study requirements.
Treatment approach: Participants will be randomly assigned to receive either phosphocreatine sodium or a placebo (saline solution) through an infusion directly into the bloodstream. The study team will carefully monitor patients throughout their participation to track recovery progress, hospital stay duration, and overall health outcomes. The trial is designed to provide clear evidence about whether phosphocreatine sodium offers meaningful benefits for patients in emergency medical situations.
Investigational drug: The trial is testing phosphocreatine sodium, a metabolic agent that works at the cellular level to provide quick energy to cells, particularly in muscles and the brain. This energy boost may help stabilize cellular functions during acute stress and critical health events. The treatment is administered intravenously and is being studied specifically for its potential to improve outcomes in medical emergency situations.
Summary
Currently, there is one active clinical trial investigating treatment options for patients experiencing tachypnoea and related emergency medical conditions. This trial is taking place in Italy and focuses on evaluating phosphocreatine sodium as a potential treatment to improve recovery outcomes for patients requiring emergency medical care. The study addresses a range of critical conditions including rapid breathing, abnormal heart rates, respiratory arrest, and changes in consciousness level.
The trial represents an important effort to find new ways to help patients in emergency situations recover more quickly and spend fewer days in the hospital. By comparing phosphocreatine sodium with standard saline treatment, researchers hope to determine whether this metabolic agent can provide meaningful benefits for patients facing life-threatening health crises. The focus on days alive and out of hospital as the primary measure of success reflects a patient-centered approach to evaluating treatment effectiveness.
Patients who meet the eligibility criteria and are interested in participating should discuss this opportunity with their healthcare providers or the medical emergency teams caring for them.